Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 vs Carboplatin in Neoadjuvant HER2+ Breast Cancer
NCT07246317Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in HER2-positive breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07246317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246317.